Observational studyTechnology in cancer research & treatment
Development and Assessment of Interstitial Brachytherapy Using Individual Curved-Needle in Treatment of Recurrent Gynecological Tumors After External Beam Radiotherapy.
Observational study in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionTo evaluate the efficacy and safety of individualized curved-needle interstitial brachytherapy (ISBT) using 3D printing for recurrent gynecologic tumors.MethodThis retrospective observational study enrolled patients with pelvic recurrent gynecologic tumors from March 2022 to April 2024. All patients received external beam radiotherapy (EBRT) (40-60 Gy, 20-30 fractions), followed by individualized curved-needle ISBT using a 3D-printed applicator (12-30 Gy, 2-5 fractions). Concurrent systemic therapy was administered when necessary. Dosimetric parameters (V100%, V200%, D100%, D98%, D90%, D50%, D5cc, D2cc, D0.1cc) were assessed. Clinical outcomes and treatment-related complications were analyzed.ResultsA total of 13 patients were included, including 4 patients with prior radiation therapy and 9 without prior radiation therapy; 45 fractions of ISBT were analyzed. Central and non-central pelvic recurrences occurred in 46.2% and 53.8% of patients, respectively. Eight patients received concurrent systemic therapy. The cumulative equivalent dose in 2-Gy fractions (EQD2) to the clinical target volume of recurrence treatment was 64.87 ± 7.16 Gy for patients with prior radiation and 73.03 ± 9.95 Gy for those without prior radiation. The corresponding cumulative EQD2 to the D2cc of the bladder, rectum, and sigmoid colon were 63.98 ± 11.37 Gy vs. 79.00 ± 12.34 Gy, 61.93 ± 8.90 Gy vs. 68.44 ± 9.93 Gy, and 41.22 ± 20.79 Gy vs. 54.49 ± 7.45 Gy, respectively. At a median follow-up of 38 months, 92.3% (12/13) of patients were alive. The 2-year and 3-year local control rates were 92.3% and 82.1%, respectively. Acute Grade 3 toxicity was observed in 30.8%, and late Grade 3 toxicity in 7.7%.ConclusionIndividualized curved-needle ISBT with a 3D-printed applicator provided high-quality treatment for recurrent gynecologic tumors with favorable outcomes and acceptable toxicity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.